Skip to content
Triangle logo TriangleGet started
← Full study record

NCT05255601 · OUTCOME

Number of Participants With Laboratory Abnormalities - Part A

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma · Source last updated 2026-06-26

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
From first dose to 30 days post last dose (Up to approximately 8 months)

What was measured

Number of participants with Grade ≥ 3 laboratory abnormalities in hematology and serum chemistry. Grade 3=severe Grade 4=life-threatening Grade 5=death

Analysis population: All treated participants in part A

Groups in this outcome

Part A - Flat Dosing (AF)

Participants received treatment with Relatlimab 160 mg + Nivolumab 480 mg Q4W

Part A - Age/Weight-based Dosing (AW)

Participant received treatment with Relatlimab 2 mg/kg + Nivolumab 6 mg/kg Q4W

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Part A - Flat Dosing (AF)4
Part A - Age/Weight-based Dosing (AW)1

Reported measurements

Grade ≥ 3 Hematology
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Part A - Flat Dosing (AF)1Not reportedNot reportedNot reportedNot reported
Part A - Age/Weight-based Dosing (AW)0Not reportedNot reportedNot reportedNot reported
Grade ≥ 3 Serum Chemistry
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Part A - Flat Dosing (AF)0Not reportedNot reportedNot reportedNot reported
Part A - Age/Weight-based Dosing (AW)0Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        1
      2. group Id
        OG001
        value
        0
    title
    Grade ≥ 3 Hematology
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        0
    title
    Grade ≥ 3 Serum Chemistry
denoms
  1. counts
    1. group Id
      OG000
      value
      4
    2. group Id
      OG001
      value
      1
    units
    Participants
description
Number of participants with Grade ≥ 3 laboratory abnormalities in hematology and serum chemistry. Grade 3=severe Grade 4=life-threatening Grade 5=death
groups
  1. description
    Participants received treatment with Relatlimab 160 mg + Nivolumab 480 mg Q4W
    id
    OG000
    title
    Part A - Flat Dosing (AF)
  2. description
    Participant received treatment with Relatlimab 2 mg/kg + Nivolumab 6 mg/kg Q4W
    id
    OG001
    title
    Part A - Age/Weight-based Dosing (AW)
param Type
COUNT_OF_PARTICIPANTS
population Description
All treated participants in part A
reporting Status
POSTED
time Frame
From first dose to 30 days post last dose (Up to approximately 8 months)
title
Number of Participants With Laboratory Abnormalities - Part A
type
PRIMARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice